EN2207 - EN2207: UW Diabetes ECHO Project

Tuesday, March 1, 2022, 12:00 AM - Tuesday, February 28, 2023, 11:00 PM, Online, Seattle, WA

AMA PRA Category 1 Credits™ (16.00 hours), Non-Physician (16.00 hours)

Project ECHO (Extension for Community Healthcare Outcomes) is a collaborative model of medical education and care management that seeks to empowers clinicians everywhere to provide better care to more people, right where they live. The focus of this ECHO project is to provide the enhanced diabetes knowledge to clinicians that will allow them to improve diabetes care to patients in underserved areas by viewing on-demand learning from recorded sessions.  The format is a series of 16 on-demand sessions recorded from virtual telementoring conferences, each about 1 hour. Each session includes about 25-40 minutes didactic presentation(s) and 25-40 minutes with community provider case discussion and Q&A.

Registration
All participants will be asked to pay a one-time fee of $30 to access the modules below. This fee covers access to the online content for the entire 16 modules listed below. Once you have paid and registered, you will receive an email when your payment is processed with instructions on how to access the content and provided a PROMO code.  Please reference that attachment on your receipt.  Registration for each individual module is also available for $25 each.

SESSION/CONTENT LISTING

These sessions can be accessed in any order but are best completed in chronological order for educational purposes:

Pre-Survey

· Session 1: Diabetes Guidelines Update by Savitha Subramanian, M.D. (handout)

· Session 2: Core Nutrition, Exercise Changes and Diabetes Medications for Weight Loss by Laura Montour, M.D. (handout)

· Session 3: Type 1 Diabetes vs. Type 2 Diabetes by Maria Belén Menucci, M.D. (handout)

· Session 4: Diabetes Medications Part 1: Use of Older Diabetes Medications with Focus on Cardiovascular and Renal Data by Nicole Ehrhardt, M.D. (handout)

· Session 5: Diabetes Medications Part 2: Use of Newer Diabetes Medications with Focus on Cardiovascular and Renal Data by Nicole Ehrhardt, M.D. (handout)

· Session 6: Initiating and Understanding Role/Place of Insulin in Type 2 Management by Barbra Onumah, M.D. (handout)

· Session 7: Motivational Tools for Diabetes and Remoting Monitoring: Glucose Meters and Continuous Glucose Monitoring Devices by Allison Brunner, MSN, RN, CDCES (handout)

· Session 8: Diabetes and Depression by Alison Ward, PhD (handout)

· Session 9: Diabetes and Heart Disease by Kelley Branch, MD, MSc, FACC, FSCCT (handout)

· Session 10: Diabetes Partnership, Cultural Sensitivity and Advocacy for Equality in Diabetes Management by Lorena Wright, M.D. (handout)

· Session 11: Diabetes in the Time of COVID-19 by Irl Hirsch, M.D. (handout)

· Session 12: Beyond Glycemic Control: Use of Diabetes Medications for Cardiovascular and Renal Indications by Gail Nunlee-Bland, M.D. (handout)

· Session 13: Retinopathy/Eye Disease: Primary Care “Pearls” by Susan Dini, OD (handout)

· Session 14: Podiatry: Clinical Pearls in Diabetes by Katrina Sullivan, DPM (handout)

· Session 15: Hypertension: Beyond the Angiotensin-converting enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARB) in Diabetes and the Time of Coronavirus (COVID)-19 by Nayan Arora, M.D. (handout)

· Session 16: Medications to Combat Insulin Resistance in Antipsychotics and Human Immunodeficiency Virus (HIV) Medications by Nicole Ehrhardt, M.D. (handout)

Post-Survey--> A post-survey link will be sent upon completion of the sessions. Your completion is appreciated.

METHOD OF PARTICIPATION
In order to complete this activity, access to the internet and a device is required. You must receive a minimum passing score of 80% on each module post-test (max. 2 attempts) in order to receive your CME credit. Each module will have a required pre-test, followed by the educational content, a post-test and evaluation. It is important to know that once you have started the Post-Test (Examination), if you exit the Post-Test without responding to all questions, it will be counted as a failed attempt. Only two (2) attempts are permitted.  To access the content, select a session from the list above.  After you have reviewed the content information, select the tests tab to be taken to the content.

INTENDED AUDIENCE
This educational program is intended for physicians, advanced practice providers, nurses, pharmacists, residents and fellows in primary care.

OBJECTIVES Upon completion of this activity, attendees should be able to:

• Use evidence-based strategies to improve overall management of type 2 diabetes.
• Discuss and review new diabetes medications and use evidence-base strategies for clinical indications for use.
• Enhance the use of multi-disciplinary approaches to diabetes management through case based learning.

DATE
Date of original release: March 1, 2022
Termination date: February 28, 2023

PLANNERS DISCLOSURE(S): All relevant financial relationships have been mitigated.

• Nicole Ehrhardt, M.D.: Consultant: Dexcom, NovoNordisk; Educational Grant: NovoNordisk, Merck; Investigator: Dexcom.
• Lorena Wright, M.D.: None.
• Savitha Subramanian, M.D.: Advisory Board for Abbott Diabetes Care.

TECHNICAL REQUIREMENTS
Minimum browser requirements for successful access and completion for this activity are as follows: Chrome version 70.0 or newer | Firefox version 63.0 or newer

COMMERCIAL SUPPORT
The University of Washington School of Medicine gratefully acknowledges receipt of an educational grant in support of this Continuing Medical Education activity from NovoNordisk.

Reference list

Accreditation with Commendation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The University of Washington School of Medicine designates this Enduring Material for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation of Relevant Financial Relationships

The University of Washington School of Medicine requires any person in control of content disclose any financial relationships with ineligible companies whose products or services are discussed in educational presentations.  Significant relationships include receiving from an ineligible company research grants, consultancies, honoraria and travel, or other benefits or having a self-managed equity interest in a company.  Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The ACCME defines an ineligible company as a company” whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”

The University of Washington School of Medicine, as part of its accreditation from the Accreditation Council on Continuing Medical Education (ACCME), is required to “mitigate” any conflicts prior to the educational program.  Therefore, in light of the relationships/affiliations designated, each person in control of content has attested that:
recommendations for patient care are based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options;
all scientific research referred to, reported, or used in this educational activity in support or justification of a patient care recommendation conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation;
·new and evolving topics for which there is a lower (or absent) evidence base are clearly identified as such;
content excludes any advocacy for, or promotion of, unscientific approaches to diagnosis or therapy, or recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

Planners Disclosure(s):

• Nicole Ehrhardt, M.D.: Consultant: Dexcom, NovoNordisk; Educational Grant: NovoNordisk, Merck; Investigator: Dexcom
• Lorena Wright, M.D.: None
• Savitha Subramanian, M.D.: Advisory board for Abbott Diabetes Care.

All relevant financial relationships have been mitigated.

No faculty are available for this activity at this time.

The University of Washington School of Medicine gratefully acknowledges receipt of an educational grant in support of this Continuing Medical Education activity from:

NovoNordisk